National Health Research Institutes

Leu-Wei Lo

Chung-Shi Yang

Wei-Neng Liao

Chia-Hung Lee

Chung-Yuan Mou

Yeu-Kuang Hwu

Shu-Yi Lin

Jen-Kun Chen

Lin-Ai Tai

Yu-Chao Wang

Yi-Ting Wu

Shin-Hsun Cheng

Shih-Hsun Cheng

Fong-Sian Lin

Yu-Jing Wang

Yao-Chen Chuang

The present invention relates to a new type of metabolizable flower-like gold nanodandelion (GND), which possesses features: (1) large scale green synthesis with high monodispersity and a circa 100% yield; (2) cellular/physiological degradability; (3) precision control of the shape, petal number and size; (4) highly efficient radiotheranostics encompassing better enhanced CT contrast and pronounced x-ray induced ROS generation than conventional spherical AuNP.

Precision control of large-scale green synthesis of biodegradable gold nanodandelions as potential radiotheranostics

A method for prevention and/or treatment of steatorrhea in a subject is disclosed. The method comprises administering to the subject a composition comprising mesoporous silica nanoparticles (MSNs) in an amount effective for prevention and/or treatment of steatorrhea in the subject

Mesoporous silica nanoparticles for oil absorption

A method of synthesizing ligand-conjugated gold nanoparticles (AuNPs) is disclosed. The method comprises: a) providing an amine-modified silica particle; b) providing a solution comprising Auions; c) suspending the amine-modified silica particle in the solution comprising Auions; d) allowing the Auions to be adsorbed and/or immobilized onto the surface of the amine-modified silica particle; e) exposing the Auions immobilized onto the surface of the amine-modified silica particle to radiation to obtain bare gold nanoparticles (AuNPs) adsorbed and/or immobilized onto the surface of the amine-modified silica particle, wherein the bare AuNPs are without organic surface modifications; and f) reacting a ligand with the bare AuNPs adsorbed and/or immobilized onto the surface of the amine-modified SiNP and thereby obtain ligand-conjugated gold nanoparticles (AuNPs).

Solid phase gold nanoparticle synthesis

A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si&#x2014;OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si&#x2014;OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug.

Charged mesoporous silica nanoparticle-based drug delivery system for controlled release and enhanced bioavailability

A blood flow control system, tension adjustable instrument and a method are disclosed. The blood flow control system comprises a detecting unit, a computing and a tension adjustable instrument. The detecting unit real-time monitors the biomolecular response condition of a living organ, and the computing unit dynamically controls the tension adjustable instrument to adjust the tension of the blood vessel based on the detecting result. Therefore the blood flow control system can maintain the biomolecular response condition over a predetermined range to reduce the risk of the liver organ being damaged and augment the curability.

Blood flow control system, tension adjustable instrument and method thereof

A quantum dot (QD) conjugate comprises a QD and a ligand conjugated with the QD, in which the ligand has at least one thiol and at least one other functional group. The QD conjugate may further comprise a bioactive agent covalently coupled to the ligand to form a bioactive agent-tagged QD conjugate. A method for preparing a QD conjugate comprises the steps of: (1) providing a solution comprising a QD encapsulated within a dendrimer; (2) adding into the solution a ligand; and (3) allowing an exchange between the ligand and the dendrimer for the QD to obtain a ligand-QD conjugate, in which the ligand is covalently conjugated to the surface of the QD. The method may further comprise the step of coupling the ligand-QD conjugate to a bioactive agent to obtain a bioactive agent-tagged ligand-QD conjugate.

Method for making a ligand-quantum dot conjugate

Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.

Growing community of inventors

Taipei, Taiwan

Leu-Wei Lo